Payment overview · 2025
General Payments
$509.93
6 reported records · 5 companies
Healthcare provider profile · identity verified
Stacy Bowen, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · TOLEDO, OH · NPI 1295717338
Verified facts
What the public records show
CMS Open Payments records show Stacy Bowen, D.O. received $509.93 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $128.80 | 25.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.56 | 24.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $118.96 | 23.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $105.47 | 20.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.14 | 6.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $509.93 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $128.80 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $124.56 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $118.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $105.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.14 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 775 | 202 |
| Levothyroxine Sodium | Levothyroxine Sodium | 565 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 425 | 112 |
| Omeprazole | Omeprazole | 403 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 391 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 350 | 84 |
| Lisinopril | Lisinopril | 314 | 94 |
| Metformin Hcl | Metformin Hcl | 252 | 67 |
| Losartan Potassium | Losartan Potassium | 251 | 61 |
| Gabapentin | Gabapentin | 228 | 56 |
| Simvastatin | Simvastatin | 224 | 64 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 204 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 48 |
| Potassium Chloride | Potassium Chloride | 189 | 57 |
| Meloxicam | Meloxicam | 186 | 45 |
| Alprazolam | Alprazolam | 182 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 50 |
| Farxiga | Dapagliflozin Propanediol | 172 | 32 |
| Furosemide | Furosemide | 168 | 41 |
| Metformin Hcl Er | Metformin Hcl | 164 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 29 |
| Montelukast Sodium | Montelukast Sodium | 161 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 155 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 145 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 57 |
| Bupropion Xl | Bupropion Hcl | 143 | 39 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 140 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 138 | 38 |
| Famotidine | Famotidine | 125 | 18 |
| Januvia | Sitagliptin Phosphate | 122 | 25 |
| Carvedilol | Carvedilol | 121 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 118 | 17 |
| Spironolactone | Spironolactone | 117 | 35 |
| Celecoxib | Celecoxib | 106 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 27 |
| Tramadol Hcl | Tramadol Hcl | 99 | 28 |
| Fenofibrate | Fenofibrate | 97 | 22 |
| Ozempic | Semaglutide | 94 | 18 |
| Alendronate Sodium | Alendronate Sodium | 92 | 21 |
| Eliquis | Apixaban | 92 | 24 |
| Trazodone Hcl | Trazodone Hcl | 92 | 30 |
| Allopurinol | Allopurinol | 90 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 36 |
| Sertraline Hcl | Sertraline Hcl | 88 | 30 |
| Jardiance | Empagliflozin | 86 | 20 |
| Bumetanide | Bumetanide | 81 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 60 |
| Trulicity | Dulaglutide | 78 | 15 |
| Aripiprazole | Aripiprazole | 76 | 14 |
| Levofloxacin | Levofloxacin | 75 | 68 |
| Ezetimibe | Ezetimibe | 73 | 28 |
| Testosterone Cypionate | Testosterone Cypionate | 73 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 14 |
| Glimepiride | Glimepiride | 69 | 19 |
| Mounjaro | Tirzepatide | 69 | 16 |
| Estradiol | Estradiol | 66 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 17 |
| Synthroid | Levothyroxine Sodium | 64 | 13 |
| Prednisone | Prednisone | 63 | 56 |
| Nifedipine Er | Nifedipine | 61 | 13 |
| Fenofibrate | Fenofibrate,micronized | 60 | 18 |
| Atenolol | Atenolol | 58 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 16 |
| Topiramate | Topiramate | 49 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | 11 |
| Fluconazole | Fluconazole | 47 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 22 |
| Donepezil Hcl | Donepezil Hcl | 42 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 41 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 19 |
| Nystatin | Nystatin | 40 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 11 |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 36 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 21 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 30 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Vraylar | Cariprazine Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Kerendia | Finerenone | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 15 |
| Diazepam | Diazepam | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Risperidone | Risperidone | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $509.93 · 6 records | ABBVIE INC. | Auvelity, BOTOX, CAPLYTA, Cologuard Collection Kit, JOURNAVX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error